risperidone has been researched along with Pervasive Child Development Disorders in 72 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients." | 9.14 | Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. ( Anderson, GM; Buitelaar, JK; Franke, B; Hoekstra, PJ; Lahuis, BE; Minderaa, RB; Mulder, EJ; Mulder, H; Scahill, L; Troost, PW, 2010) |
| "Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults." | 9.08 | A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. ( Carlson, DC; Cohen, DJ; Holmes, JP; McDougle, CJ; Pelton, GH; Price, LH, 1998) |
| "To review the clinical trials investigating the efficacy and safety of risperidone in the treatment of children with autism spectrum disorder (ASD)." | 8.83 | Role of risperidone in children with autism spectrum disorder. ( Chavez, B; Chavez-Brown, M; Rey, JA, 2006) |
| "To report a case of risperidone-induced Pisa syndrome in a patient with multiple sclerosis (MS) that resolved with lurasidone, recurred with chlorpromazine, and was complicated by possible drug-drug interactions." | 7.79 | Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine. ( Diefenderfer, LA; Iuppa, CA, 2013) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 7.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "8 years) with bipolar disorder (25 mixed and 3 hypomanic) who had been treated with risperidone were identified." | 7.70 | Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. ( Biederman, J; Frazier, JA; Kim, GS; Meyer, MC; Shapiro, S; Spencer, TJ; Wilens, TE; Wozniak, J, 1999) |
| "This study identified subtypes of aggression in a sample of 206 children with autism spectrum disorder (ASD) who participated in 2 risperidone trials." | 5.19 | Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems. ( Aman, MG; Arnold, LE; Bearss, K; Carroll, D; Hallett, V; Handen, BL; Johnson, C; Lecavalier, L; McCracken, JT; McDougle, CJ; Scahill, L; Sukhodolsky, DG; Swiezy, N; Tierney, E; Vitiello, B, 2014) |
| "Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients." | 5.14 | Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. ( Anderson, GM; Buitelaar, JK; Franke, B; Hoekstra, PJ; Lahuis, BE; Minderaa, RB; Mulder, EJ; Mulder, H; Scahill, L; Troost, PW, 2010) |
| "To investigate the efficacy and safety of risperidone for the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders (PDD)." | 5.11 | Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. ( Carroll, A; Dunbar, F; Orlik, H; Schulz, M; Shea, S; Smith, I; Turgay, A, 2004) |
| "Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults." | 5.08 | A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. ( Carlson, DC; Cohen, DJ; Holmes, JP; McDougle, CJ; Pelton, GH; Price, LH, 1998) |
| "To review the clinical trials investigating the efficacy and safety of risperidone in the treatment of children with autism spectrum disorder (ASD)." | 4.83 | Role of risperidone in children with autism spectrum disorder. ( Chavez, B; Chavez-Brown, M; Rey, JA, 2006) |
| "The most convincing evidence of the efficacy of atypical neuroleptics in children and adolescents concerns clozapine in the treatment of schizophrenia." | 4.80 | Use of atypical neuroleptics in child and adolescent psychiatry. ( Laor, N; Toren, P; Weizman, A, 1998) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| " Prolactin levels, hyperprolactinemia, risperidone levels, and 9-hydroxyrisperidone levels were assessed and the participants were genotyped for common CYP2D6 polymorphisms and the Taq1A allele of the dopamine D2 receptor gene." | 3.79 | The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. ( Boot, AM; Buitelaar, JK; Franke, B; Galesloot, TE; Roke, Y; van Harten, PN, 2013) |
| "To report a case of risperidone-induced Pisa syndrome in a patient with multiple sclerosis (MS) that resolved with lurasidone, recurred with chlorpromazine, and was complicated by possible drug-drug interactions." | 3.79 | Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine. ( Diefenderfer, LA; Iuppa, CA, 2013) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 3.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "Although hyperprolactinemia is a common side effect during risperidone treatment in adult patients, no information is available on young children." | 3.71 | Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. ( Cosenza, A; Masi, G; Mucci, M, 2001) |
| "8 years) with bipolar disorder (25 mixed and 3 hypomanic) who had been treated with risperidone were identified." | 3.70 | Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. ( Biederman, J; Frazier, JA; Kim, GS; Meyer, MC; Shapiro, S; Spencer, TJ; Wilens, TE; Wozniak, J, 1999) |
| "Autism spectrum disorder is characterized by difficulty with social communication and restricted, repetitive patterns of behavior, interest, or activities." | 2.53 | Autism Spectrum Disorder: Primary Care Principles. ( Sanchack, KE; Thomas, CA, 2016) |
| "This article gives an overview of the pharmacokinetic profile of risperidone and a comprehensive review of treatment studies regarding the use of risperidone in ASD." | 2.52 | Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder. ( Dietrich, A; Dinnissen, M; Hoekstra, PJ; van den Hoofdakker, BJ, 2015) |
| "Risperidone has been the best studied among these medications." | 2.43 | Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders. ( Dinca, O; Paul, M; Spencer, NJ, 2005) |
| " No correlation was found between risperidone dosage and either risperidone or drug metabolite plasma levels." | 1.40 | CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. ( Bar-Chaim, A; Benveniste-Levkovitz, P; Berkovitch, M; Britzi, M; Gabis, LV; Soback, S; Youngster, I; Zachor, DA; Ziv-Baran, T, 2014) |
| "Outcome measures were the Childhood Autism Rating Scale, the Children's Psychiatric Rating Scale, Clinical Global Impression (improvement score), and the Children's Global Assessment of Functioning." | 1.31 | Risperidone monotherapy in preschool children with pervasive developmental disorders. ( Cosenza, A; De Vito, G; Masi, G; Mucci, M, 2001) |
| "Weight gain was observed in 5 of 6 patients, with a median increase of 5." | 1.30 | Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. ( Armenteros, J; Munoz-Silva, DM; Pataki, C; Perry, R; Silva, RR, 1997) |
| "Risperidone was initiated at a starting dose of 0." | 1.29 | Use of risperidone in pervasive developmental disorders: a case series. ( Fisman, S; Steele, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (12.50) | 18.2507 |
| 2000's | 23 (31.94) | 29.6817 |
| 2010's | 40 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Margari, L | 1 |
| Matera, E | 1 |
| Craig, F | 1 |
| Petruzzelli, MG | 1 |
| Palmieri, VO | 1 |
| Pastore, A | 1 |
| Margari, F | 1 |
| Bachmann, CJ | 1 |
| Manthey, T | 1 |
| Kamp-Becker, I | 1 |
| Glaeske, G | 1 |
| Hoffmann, F | 1 |
| Nurmi, EL | 1 |
| Spilman, SL | 1 |
| Whelan, F | 1 |
| Scahill, LL | 1 |
| Aman, MG | 10 |
| McDougle, CJ | 17 |
| Arnold, LE | 8 |
| Handen, B | 6 |
| Johnson, C | 5 |
| Sukhodolsky, DG | 3 |
| Posey, DJ | 4 |
| Lecavalier, L | 7 |
| Stigler, KA | 7 |
| Ritz, L | 4 |
| Tierney, E | 5 |
| Vitiello, B | 8 |
| McCracken, JT | 6 |
| Roke, Y | 2 |
| van Harten, PN | 2 |
| Franke, B | 2 |
| Galesloot, TE | 1 |
| Boot, AM | 2 |
| Buitelaar, JK | 5 |
| Ameis, SH | 1 |
| Corbett-Dick, P | 1 |
| Cole, L | 1 |
| Correll, CU | 1 |
| Carroll, D | 1 |
| Hallett, V | 2 |
| Handen, BL | 1 |
| Swiezy, N | 2 |
| Bearss, K | 5 |
| Scahill, L | 11 |
| Iuppa, CA | 1 |
| Diefenderfer, LA | 1 |
| Wink, LK | 2 |
| Early, M | 2 |
| Schaefer, T | 1 |
| Pottenger, A | 1 |
| Horn, P | 1 |
| Erickson, CA | 4 |
| Adler, BA | 1 |
| Shaffer, R | 1 |
| Minshawi, N | 1 |
| Youngster, I | 1 |
| Zachor, DA | 1 |
| Gabis, LV | 1 |
| Bar-Chaim, A | 1 |
| Benveniste-Levkovitz, P | 1 |
| Britzi, M | 1 |
| Soback, S | 1 |
| Ziv-Baran, T | 1 |
| Berkovitch, M | 1 |
| Hoekstra, PJ | 5 |
| Dinnissen, M | 1 |
| Dietrich, A | 1 |
| van den Hoofdakker, BJ | 1 |
| Wong, IC | 1 |
| Hsia, Y | 1 |
| Ronsley, R | 1 |
| Nguyen, D | 1 |
| Davidson, J | 1 |
| Panagiotopoulos, C | 1 |
| Fung, LK | 1 |
| Mahajan, R | 1 |
| Nozzolillo, A | 1 |
| Bernal, P | 1 |
| Krasner, A | 1 |
| Jo, B | 1 |
| Coury, D | 1 |
| Whitaker, A | 1 |
| Veenstra-Vanderweele, J | 3 |
| Hardan, AY | 1 |
| Sanchack, KE | 1 |
| Thomas, CA | 1 |
| Dziura, J | 4 |
| Butter, E | 4 |
| Sukhodolsky, D | 1 |
| Mulick, J | 1 |
| Stigler, K | 1 |
| Wagner, A | 2 |
| Swiezy, NB | 4 |
| Sukhodolsky, DD | 2 |
| Ramadan, Y | 1 |
| Pozdol, SL | 2 |
| Nikolov, R | 2 |
| Kohn, AE | 2 |
| Koenig, K | 3 |
| Hollway, JA | 2 |
| Korzekwa, P | 2 |
| Gavaletz, A | 2 |
| Mulick, JA | 2 |
| Hall, KL | 1 |
| Trollinger, S | 1 |
| Yu, S | 3 |
| van Haaren, F | 1 |
| Lemmon, ME | 1 |
| Gregas, M | 1 |
| Jeste, SS | 1 |
| Troost, PW | 3 |
| Lahuis, BE | 3 |
| Mulder, H | 1 |
| Mulder, EJ | 1 |
| Anderson, GM | 2 |
| Minderaa, RB | 3 |
| McPheeters, ML | 2 |
| Warren, Z | 2 |
| Sathe, N | 1 |
| Bruzek, JL | 1 |
| Krishnaswami, S | 1 |
| Jerome, RN | 1 |
| Banaschewski, T | 1 |
| Poustka, L | 1 |
| Holtmann, M | 1 |
| Calarge, CA | 1 |
| Miller, del D | 1 |
| Lit, L | 1 |
| Sharp, FR | 1 |
| Bertoglio, K | 1 |
| Stamova, B | 1 |
| Ander, BP | 1 |
| Sossong, AD | 1 |
| Hendren, RL | 1 |
| Matson, JL | 1 |
| Sipes, M | 1 |
| Fodstad, JC | 1 |
| Fitzgerald, ME | 1 |
| Farmer, C | 1 |
| Eugene Arnold, L | 2 |
| Johnson, CR | 1 |
| Demb, H | 1 |
| Valicenti-McDermott, M | 1 |
| Navarro, A | 1 |
| Ayoob, KT | 1 |
| Ishitobi, M | 1 |
| Hiratani, M | 1 |
| Kosaka, H | 1 |
| Takahashi, T | 1 |
| Mizuno, T | 1 |
| Asano, M | 1 |
| Murata, T | 1 |
| Tomoda, A | 1 |
| Wada, Y | 1 |
| Frazier, TW | 1 |
| Swiezy, NG | 1 |
| Grinnon, S | 1 |
| Okada, T | 1 |
| Hasanzadeh, E | 1 |
| Mohammadi, MR | 1 |
| Ghanizadeh, A | 1 |
| Rezazadeh, SA | 1 |
| Tabrizi, M | 1 |
| Rezaei, F | 1 |
| Akhondzadeh, S | 1 |
| Venkat, A | 1 |
| Jauch, E | 1 |
| Russell, WS | 1 |
| Crist, CR | 1 |
| Farrell, R | 1 |
| Chadman, KK | 1 |
| Guariglia, SR | 1 |
| Yoo, JH | 1 |
| Nightingale, S | 1 |
| Dove, D | 1 |
| Taylor, JL | 1 |
| Sathe, NA | 1 |
| Yui, K | 1 |
| Li, X | 1 |
| Humphries, K | 1 |
| Wilson, K | 1 |
| Deng, Y | 1 |
| Tenback, D | 1 |
| Rapin, I | 1 |
| Masi, G | 4 |
| Cosenza, A | 4 |
| Mucci, M | 4 |
| Brovedani, P | 2 |
| Findling, RL | 1 |
| McNamara, NK | 1 |
| Shea, S | 1 |
| Turgay, A | 1 |
| Carroll, A | 1 |
| Schulz, M | 1 |
| Orlik, H | 1 |
| Smith, I | 1 |
| Dunbar, F | 1 |
| Kastner, TA | 1 |
| Bober, D | 1 |
| Sabzwari, U | 1 |
| Star, JE | 1 |
| Dinca, O | 1 |
| Paul, M | 1 |
| Spencer, NJ | 1 |
| Hellings, JA | 1 |
| Zarcone, JR | 1 |
| Valdovinos, MG | 1 |
| Reese, RM | 1 |
| Gaughan, E | 1 |
| Schroeder, SR | 1 |
| Chavez, B | 1 |
| Chavez-Brown, M | 1 |
| Rey, JA | 1 |
| Williams, SK | 1 |
| Dimitropoulos, A | 1 |
| Cronin, P | 1 |
| Grados, M | 1 |
| Ghuman, J | 1 |
| Lam, KS | 1 |
| McGough, J | 1 |
| Althaus, M | 1 |
| Hermans, MH | 1 |
| van Engeland, H | 1 |
| Carr, JE | 1 |
| LeBlanc, LA | 1 |
| Gadow, KD | 1 |
| Williams White, S | 1 |
| Purdon, SE | 1 |
| Lit, W | 1 |
| Labelle, A | 1 |
| Jones, BD | 1 |
| Holmes, JP | 2 |
| Bronson, MR | 1 |
| Volkmar, FR | 1 |
| Price, LH | 2 |
| Cohen, DJ | 2 |
| Demb, HB | 1 |
| Fisman, S | 2 |
| Steele, M | 2 |
| Pipher, B | 1 |
| Perry, R | 1 |
| Pataki, C | 1 |
| Munoz-Silva, DM | 1 |
| Armenteros, J | 1 |
| Silva, RR | 1 |
| Carlson, DC | 1 |
| Pelton, GH | 1 |
| Toren, P | 1 |
| Laor, N | 1 |
| Weizman, A | 1 |
| Frazier, JA | 1 |
| Meyer, MC | 1 |
| Biederman, J | 1 |
| Wozniak, J | 1 |
| Wilens, TE | 1 |
| Spencer, TJ | 1 |
| Kim, GS | 1 |
| Shapiro, S | 1 |
| De Vito, G | 1 |
| Buckley, PF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Emotion Awareness and Skills Enhancement (EASE) Program: A Clinical Trial[NCT03432832] | 113 participants (Actual) | Interventional | 2018-01-30 | Completed | |||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| The Effectiveness of an Attention-based Intervention for School Aged Autistic Children With Anger Regulating Problems: a Randomized Controlled Trial[NCT05221515] | 51 participants (Actual) | Interventional | 2011-01-01 | Completed | |||
| Effect of PLAY Project Intervention Program on Children With Autism Spectrum Disorder: A Multi-center, Randomized Control Study in China[NCT05531669] | 200 participants (Anticipated) | Interventional | 2022-08-01 | Recruiting | |||
| Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder[NCT00080145] | 124 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Cognitive-Behavioral Therapy for Irritability in Adolescents With High Functioning Autism Spectrum Disorder[NCT01631851] | 9 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| Randomized Trial of Parent Training for Young Children With Autism[NCT01233414] | 180 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)[NCT02410902] | Phase 3 | 190 participants (Actual) | Interventional | 2015-05-13 | Completed | ||
| Development and Validation of a System for the Anticipation of Challenging Behaviors of People With Autism Spectrum Disorder Based on a Smart Shirt: a Mixed-method Design[NCT05340608] | 51 participants (Actual) | Observational | 2022-06-01 | Completed | |||
| An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin[NCT02649959] | Phase 3 | 405 participants (Anticipated) | Interventional | 2015-10-31 | Active, not recruiting | ||
| Assessing the Feasibility, Acceptability, and Preliminary Efficacy of an Adaptive Intervention Approach for Children With Autism and Disruptive Behavior: A Pilot Study[NCT04204226] | 42 participants (Actual) | Interventional | 2019-12-17 | Completed | |||
| Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study[NCT00261508] | Phase 3 | 80 participants (Actual) | Interventional | 1999-08-31 | Completed | ||
| Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.[NCT00691080] | 58 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Neural Mechanisms of CBT for Anxiety in Children With Autism: Randomized Controlled Trial[NCT02725619] | 70 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study[NCT02225808] | 10 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist (ABC) - Community sub scale for Irritability/Agitation (ABC-I) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-I is one of five discrete sub scales measured by the ABC. The scale range is 0-45. A higher score reflects higher severity of symptoms (irritability). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. The score was automatically calculated by the EDC. (NCT02410902)
Timeframe: Screening through Week 12/Termination
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -8.0 |
| Placebo | -5.5 |
Secondary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist- Community (ABC) sub scale for Lethargy / Social Withdrawal (ABC-L) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-L is one of five discrete sub scales measured by the ABC. The scale range is 0-48. A higher score reflects higher severity of symptoms (lethargy). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. (NCT02410902)
Timeframe: Screening through Week 12/Termination.
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -7.9 |
| Placebo | -6.6 |
18 reviews available for risperidone and Pervasive Child Development Disorders
| Article | Year |
|---|---|
Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder.
Topics: Animals; Antipsychotic Agents; Child Development Disorders, Pervasive; Disease Management; Drug Eval | 2015 |
Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Child; Child Development D | 2016 |
Autism Spectrum Disorder: Primary Care Principles.
Topics: Antipsychotic Agents; Aripiprazole; Asperger Syndrome; Autism Spectrum Disorder; Autistic Disorder; | 2016 |
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Chil | 2008 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
[Autism and ADHD across the life span. Differential diagnoses or comorbidity?].
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Dis | 2011 |
Issues in the management of challenging behaviours of adults with autism spectrum disorder.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Behavior Therapy; Child; Child Development D | 2011 |
[The mental disorder and obsessive-compulsive spectrum disorders in childhood ].
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Clomipramine; Cognitive Behavio | 2011 |
Care of the patient with an autism spectrum disorder by the general physician.
Topics: Adolescent; Antipsychotic Agents; Caregivers; Child; Child Development Disorders, Pervasive; Child, | 2012 |
New directions in the treatment of autism spectrum disorders from animal model research.
Topics: Adolescent; Adolescent Behavior; Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous | 2012 |
Medications for adolescents and young adults with autism spectrum disorders: a systematic review.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; | 2012 |
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; | 2004 |
Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders.
Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Child Development Disorders, Perv | 2005 |
Risperidone in pervasive developmental disorders.
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Diabetes Mellitus; Expert Testi | 2005 |
Role of risperidone in children with autism spectrum disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Double-Blind | 2006 |
Autism spectrum disorders in early childhood: an overview for practicing physicians.
Topics: Asperger Syndrome; Autistic Disorder; Behavior Therapy; Behavioral Medicine; Child; Child Developmen | 2007 |
Use of atypical neuroleptics in child and adolescent psychiatry.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Child; Child Development Diso | 1998 |
Broad therapeutic uses of atypical antipsychotic medications.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Child Development Disorders, P | 2001 |
17 trials available for risperidone and Pervasive Child Development Disorders
| Article | Year |
|---|---|
Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems.
Topics: Adolescent; Aggression; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Child; | 2014 |
Trial design challenges when combining medication and parent training in children with pervasive developmental disorders.
Topics: Adolescent; Aggression; Behavior Therapy; Child; Child Development Disorders, Pervasive; Combined Mo | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.
Topics: Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Body Mass Index; Child; Child D | 2010 |
Predictors and moderators of parent training efficacy in a sample of children with autism spectrum disorders and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Child Development Disorders, Perv | 2012 |
Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems.
Topics: Adaptation, Psychological; Adolescent; Antipsychotic Agents; Asperger Syndrome; Autistic Disorder; C | 2012 |
A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders.
Topics: Administration, Oral; Antipsychotic Agents; Child; Child Behavior; Child Development Disorders, Perv | 2012 |
Research Units of Pediatric Psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: one-year follow-up.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Child Develo | 2012 |
Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, Preschool; D | 2013 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; | 2005 |
Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.
Topics: Antipsychotic Agents; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasi | 2006 |
Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention; Child; Child Behavior Disorders; Child Deve | 2006 |
Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, | 2007 |
Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.
Topics: Adolescent; Adolescent Behavior; Child; Child Behavior; Child Development Disorders, Pervasive; Dopa | 1997 |
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Aggression; Antipsychotic Agents; Autistic Disorder; Child Developme | 1998 |
Open trial of risperidone in 24 young children with pervasive developmental disorders.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2001 |
37 other studies available for risperidone and Pervasive Child Development Disorders
| Article | Year |
|---|---|
Tolerability and safety profile of risperidone in a sample of children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Body Composit | 2013 |
Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Central Nervous System Stimula | 2013 |
Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.
Topics: Adolescent; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Amidohydrolases; Antipsychotic Agents; Bo | 2013 |
The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Topics: Adolescent; Alleles; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Chil | 2013 |
Decision making and antipsychotic medication treatment for youth with autism spectrum disorders: applying guidelines in the real world.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child | 2013 |
Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine.
Topics: Adult; Antipsychotic Agents; Child Development Disorders, Pervasive; Chlorpromazine; Gait Ataxia; Hu | 2013 |
Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Child; Child Development Disorders, | 2014 |
Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Child D | 2015 |
CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, Preschool; C | 2014 |
Risperidone for non-psychotic disorders in paediatric patients: which child is to benefit?
Topics: Antipsychotic Agents; Child Development Disorders, Pervasive; Cytochrome P-450 CYP2D6; Female; Human | 2014 |
Authors' response to Bachmann and Hoffman's comments on psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study.
Topics: Child Development Disorders, Pervasive; Female; Humans; Male; Methylphenidate; Risperidone; Valproic | 2015 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Risperidone and parent training in pervasive developmental disorders.
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Health Education; Humans; Paren | 2010 |
Academy of Medicine Singapore-Ministry of Health clinical practice guidelines: Autism Spectrum Disorders in pre-school children.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Benzodiazepines; Central Nervous System Sti | 2010 |
Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, Preschool; F | 2011 |
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Topics: Adolescent; Aging; Antipsychotic Agents; Body Mass Index; Child; Child Development Disorders, Pervas | 2011 |
Gene expression in blood is associated with risperidone response in children with autism spectrum disorders.
Topics: Antipsychotic Agents; Biomarkers, Pharmacological; Child; Child Development Disorders, Pervasive; Ch | 2012 |
The effect of long-term use of risperidone on body weight of children with an autism spectrum disorder.
Topics: Antipsychotic Agents; Body Weight; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone.
Topics: Adolescent; Aripiprazole; Child; Child Development Disorders, Pervasive; Drug Substitution; Female; | 2012 |
Friends not foes: combined risperidone and behavior therapy for irritability in autism.
Topics: Adaptation, Psychological; Antipsychotic Agents; Child Behavior Disorders; Child Development Disorde | 2012 |
Autism spectrum disorders.
Topics: Adolescent; Aripiprazole; Child Development Disorders, Pervasive; Child, Preschool; Clinical Trials | 2012 |
[Useful pharmacologic treatment in impaired social interaction in autism spectrum disorders].
Topics: Administration, Inhalation; Antipsychotic Agents; Arachidonic Acid; Aripiprazole; Child Development | 2012 |
Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; | 2012 |
The autistic-spectrum disorders.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2002 |
A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2003 |
Methylphenidate an effective treatment for ADHD?
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Auti | 2004 |
Use of risperidone in developmentally disabled children.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Diagnosis, D | 2005 |
Risperidone in a very young child with PDD.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2005 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Risperidone in the treatment of pervasive developmental disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Perv | 1994 |
Risperidone in young children with pervasive developmental disorders and other developmental disabilities.
Topics: Aggression; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Preschool; Huma | 1996 |
Use of risperidone in pervasive developmental disorders: a case series.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Dopamine; Female; H | 1996 |
Risperidone in PDD.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Humans; Risperidone | 1998 |
Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up.
Topics: Adolescent; Anger; Child; Child Development Disorders, Pervasive; Dopamine Antagonists; Female; Huma | 1997 |
Risperidone treatment for juvenile bipolar disorder: a retrospective chart review.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; C | 1999 |
Risperidone monotherapy in preschool children with pervasive developmental disorders.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Child Development Disorder | 2001 |
Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.
Topics: Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2001 |